¸¸¼º Á¤¸Æ Æó»ö Ä¡·á ½ÃÀå : Á¦Ç° À¯Çüº°, Ä¡·á À¯Çüº°, Áø´Üº°, ÃÖÁ¾ ¿ëµµº°, ±¹°¡º°, Áö¿ªº°, ¼¼°è »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2025-2032³â)
Chronic Venous Occlusions Treatment Market, By Product Type, By Treatment Type, By Diagnosis, By End-User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
»óǰÄÚµå : 1709478
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2025³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 303 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,535,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,488,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,884,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸¸¼º Á¤¸Æ Æó»ö Ä¡·á½ÃÀå ±Ô¸ð´Â 2024³â 72¾ï943¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2025³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 5.80%·Î ¼ºÀåÇÒ°ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸¸¼º Á¤¸Æ Æó»ö Ä¡·á ½ÃÀå - ½ÃÀå ¿ªÇÐ

Á¤¸Æ ÁúȯÀÇ À¯º´·üÀÇ »ó½Â°ú ±â¼úÀÇ Áøº¸°¡ ¸¸¼º Á¤¸Æ Æó»ö Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎ

¸¸¼ºÁ¤¸ÆºÎÀü°ú ½ÉºÎÁ¤¸ÆÇ÷ÀüÁõ µî Á¤¸ÆÁúȯÀÇ À¯º´·ü »ó½Â°ú Àúħ½ÀÄ¡·á±â¼úÀÇ Áøº¸°¡ ¸¸¼º Á¤¸Æ Æó»ö Ä¡·á½ÃÀåÀÇ ¼ºÀåÀ» Å©°Ô °ßÀÎÇϰí ÀÖ½À´Ï´Ù. Á¤¸ÆÁúȯÀº ¼¼°è ¼ºÀÎÀα¸ÀÇ ¾à 30%°¡ º´À» ¾Î°í ÀÖÀ¸¸ç, °í·ÉÈ­¿Í ÁÂ½Ä »ýȰ ½ºÅ¸ÀÏÀÌ ºÎ´ãÁõÀÇ ¿øÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿¬°£ 60¸¸ °Ç ÀÌ»óÀÇ Á¤¸Æ Ç÷Àü »öÀüÁõÀÌ »õ·Ó°Ô Áø´ÜµÇ°í ÀÖ½À´Ï´Ù. »ýü Èí¼ö ½ºÅÙÆ®¿Í °³¼±µÈ Ç÷Àü ¿ëÇØ ±â¼ú°ú °°Àº Çõ½ÅÀº Ä¡·á °á°ú¸¦ Çâ»ó½Ã۰í ÀÖÀ¸¸ç, ½ÅÈï °æÁ¦±¹ÀÇ ÀÇ·á ÀÎÇÁ¶ó¸¦ °³¼±Çϱâ À§ÇÑ Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê´Â ½ÃÀå È®ÀåÀ» À§ÇÑ »õ·Î¿î ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª, Ä¡·áºñÀÇ »ó½Â°ú Áö¹æ¿¡¼­ÀÇ °íµµ ÀÇ·á ¾×¼¼½ºÀÇ Á¦ÇÑÀ̶ó°í ÇÏ´Â °úÁ¦´Â ¿©ÀüÈ÷ º¸±ÞÀÇ Áß¿äÇÑ À庮ÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¸¸¼º Á¤¸Æ Æó»ö Ä¡·á ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®·Â

¿ì¸® ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®ÀÇ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2025-2032³â)¿¡ ¾à 5.80%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

Á¦Ç° À¯Çüº°·Î, Á¤¸Æ ½ºÅÙÆ®¿Í Ç×ÀÀ°íÁ¦´Â 2024³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Ä¡·á À¯Çüº°·Î Á¤¸Æ ³» ÀýÁ¦¿Í Ç÷Àü ¿ëÇØ ¿ä¹ýÀÌ 2024³â ÁÖ¿ä Ä¡·á À¯ÇüÀ̾ú½À´Ï´Ù.

Áø´Üº°·Î´Â µàÇ÷º½º ÃÊÀ½ÆÄ°¡ 2024³âÀÇ ÁÖ¿ä Áø´ÜÀ̾ú½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2024³â ¸ÅÃâÀ» À̲ø¾ú½À´Ï´Ù.

¸¸¼º Á¤¸Æ Æó»ö Ä¡·á ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

¼¼°èÀÇ ¸¸¼º Á¤¸Æ Æó»ö Ä¡·á ½ÃÀåÀº Á¦Ç° À¯Çü, Ä¡·á À¯Çü, Áø´Ü, ÃÖÁ¾ ¿ëµµ ¹× Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº Á¦Ç° À¯Çü¿¡ µû¶ó ³× °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. Áï, ¾Ð¹Ú ½ºÅ¸Å·, Á¤¸Æ ½ºÅÙÆ®, Ç×ÀÀ°íÁ¦, °æÈ­ ¿ä¹ýÁ¦ µîÀÔ´Ï´Ù.

½ÃÀåÀº Ä¡·á À¯Çü¿¡ µû¶ó µÎ °¡Áö·Î ºÐ·ùµË´Ï´Ù. Áï, ¾Ð¹Ú ¿ä¹ý, ¾à¹° ¿ä¹ý, Á¤¸Æ ³» ¼ÒÀÛ ¿ä¹ý, ¿Ü°ú Àû °³ÀÔ, Ç÷Àü ¿ëÇØ ¿ä¹ýÀÔ´Ï´Ù.

¸¸¼º Á¤¸Æ Æó»ö Ä¡·á ½ÃÀå - Áö¸®Àû ÅëÂû

¸¸¼º Á¤¸Æ Æó»ö Ä¡·á ½ÃÀåÀº °Ç°­ °ü¸® ÀÎÇÁ¶ó, Áúº´ À¯º´·ü, ¼±Áø Ä¡·á Á¢±Ù µîÀÇ Â÷ÀÌ·Î ÀÎÇØ Å« Áö¿ª Â÷À̸¦ º¼ ¼ö ÀÖ½À´Ï´Ù. Á¶±â µµÀÔ¿¡ ÈûÀÔ¾î ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç, ¹Ì±¹Àº ½ÉºÎÁ¤¸ÆÇ÷ÀüÁõÀ̳ª ¸¸¼ºÁ¤¸ÆºÎÀüÀÇ Áõ·Ê Áõ°¡·Î Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ½Ã¾îƼºê¿¡ °ßÀÎµÇ°í ±× µÚ¸¦ À̾°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·áºñ Áõ°¡, ÀÇ·á ½Ã¼³ Á¢±Ù¼º °³¼±, Á¤¸Æ Áúȯ¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Áß±¹°ú Àεµ¿Í °°Àº ±¹°¡°¡ °ßÀοªÀ¸·Î ±Þ¼ÓÇÑ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ÇÑÆí, ¶óƾ¾Æ¸Þ¸®Ä«¿Í Áßµ¿, ¾ÆÇÁ¸®Ä«´Â ÀÇ·á ¾×¼¼½º°¡ Á¦ÇѵǾî ÀÖ´Â µîÀÇ °úÁ¦¿¡ Á÷¸éÇϰí ÀÖÁö¸¸, ÀÇ·á ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ¿Í Àúħ½À Ä¡·áÀÇ Ã¤¿ë Áõ°¡¸¦ ÅëÇØ Á¡Â÷ ½ÃÀå¿¡¼­ÀÇ Á¸À縦 È®´ëÇϰí ÀÖ½À´Ï´Ù.

¸¸¼º Á¤¸Æ Æó»ö Ä¡·á ½ÃÀå - °æÀï ±¸µµ :

¸¸¼º Á¤¸Æ Æó»ö Ä¡·á½ÃÀåÀº ±âÁ¸ÀÇ ÀÇ·á±â±â±â¾÷, ½ÅÈï±â¾÷, ±â¼ú Çõ½Å°ú ½ÃÀå È®´ë¸¦ ¸ñÀûÀ¸·Î ÇÑ Àü·«Àû Á¦ÈÞÀÇ Á¸Àç¿¡ ÀÇÇØ Ư¡Áö¾îÁö´Â °æÀï ±¸µµ¸¦ Ư¡À¸·Î ÇÕ´Ï´Ù. Medtronic, Boston Scientific, ±×¸®°í Philips Healthcare µîÀÇ ÁÖ¿ä ±â¾÷ÀÌ ½ÃÀåÀ» µ¶Á¡ÇÏ°í ±¤¹üÀ§ÇÑ Á¦Ç° Æ÷Æ®Æú¸®¿À¿Í °­·ÂÇÑ À¯Åë¸ÁÀ» Ȱ¿ëÇÏ¿© °æÀï·ÂÀ» À¯ÁöÇϰí ÀÖ½À´Ï´Ù. ¼Ò±â¾÷°ú ½ÅÈï±â¾÷µµ Æ´»õ ºÎ¹®¿Í ºñ¿ë È¿À²ÀûÀÎ Ä¡·á¿¡ ÁÖ·ÂÇÔÀ¸·Î½á °ßÀηÂÀ» ´Ã¸®°í ÀÖ½À´Ï´Ù. ÀÎÁ¤°ú ÀÓ»ó½ÃÇèÀº °æÀï·ÂÇÐ Çü¼º¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, °¢ »ç´Â ¾ö°ÝÇÑ ¾ÈÀü¼º°ú È¿´ÉÀÇ ±âÁØÀ» ÃæÁ·Çϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¸¸¼º Á¤¸Æ Æó»ö Ä¡·á ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¸¸¼º Á¤¸Æ Æó»ö Ä¡·áÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ¸¸¼º Á¤¸Æ Æó»ö Ä¡·á »ê¾÷ ¿¬±¸

Á¦5Àå ¸¸¼º Á¤¸Æ Æó»ö Ä¡·á½ÃÀå : ³ô¾ÆÁö´Â ÁöÁ¤ÇÐÀû ±äÀåÀÇ ¿µÇâ

Á¦6Àå ¸¸¼º Á¤¸Æ Æó»ö Ä¡·á ½ÃÀå »óȲ

Á¦7Àå ¸¸¼º Á¤¸Æ Æó»ö Ä¡·á ½ÃÀå-Á¦Ç° À¯Çü

Á¦8Àå ¸¸¼º Á¤¸Æ Æó»ö Ä¡·á ½ÃÀå-Ä¡·á À¯Çüº°

Á¦9Àå ¸¸¼º Á¤¸Æ Æó»ö Ä¡·á½ÃÀå- Áø´Üº°

Á¦10Àå ¸¸¼º Á¤¸Æ Æó»ö Ä¡·á½ÃÀå- ÃÖÁ¾¿ëµµº°

Á¦11Àå ¸¸¼º Á¤¸Æ Æó»ö Ä¡·á½ÃÀå-Áö¿ª

Á¦12Àå ÁÖ¿ä º¥´õ ºÐ¼® - ¸¸¼º Á¤¸Æ Æó»ö Ä¡·á ¾÷°è

Á¦13Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§Àû Àü¸Á

SHW
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Chronic Venous Occlusions Treatment Market size was valued at US$ 7,209.43 Million in 2024, expanding at a CAGR of 5.80% from 2025 to 2032.

The Chronic Venous Occlusions (CVO) Treatment Market focuses on addressing blockages in the venous system, often caused by deep vein thrombosis or chronic venous insufficiency, through interventions like angioplasty, stenting, and thrombolysis. Increasing prevalence of venous diseases, advancements in minimally invasive surgical techniques, and rising awareness about early diagnosis are propelling market growth, with over 30% of adults estimated to suffer from some form of venous disorder globally. However, high treatment costs and limited access to advanced healthcare in developing regions act as significant restraints. Opportunities lie in the development of innovative bioabsorbable stents and the expansion of telemedicine for post-treatment care, particularly in underserved areas. Additionally, the growing aging population, which is more susceptible to venous disorders, further underscores the potential for market expansion.

Chronic Venous Occlusions Treatment Market- Market Dynamics

Rising Prevalence of Venous Disorders and Technological Advancements to Drive Chronic Venous Occlusions Treatment Market Growth

The rising prevalence of venous disorders, such as chronic venous insufficiency and deep vein thrombosis, coupled with advancements in minimally invasive treatment technologies, is significantly driving the growth of the Chronic Venous Occlusions (CVO) Treatment Market. According to the World Health Organization (WHO), venous diseases affect approximately 30% of the global adult population, with aging populations and sedentary lifestyles contributing to the increasing burden. For instance, the National Institutes of Health (NIH) reports that over 600,000 new cases of venous thromboembolism are diagnosed annually in the United States alone. Innovations like bioabsorbable stents and improved thrombolysis techniques are enhancing treatment outcomes, while government initiatives to improve healthcare infrastructure in emerging economies are creating new opportunities for market expansion. However, challenges such as high treatment costs and limited access to advanced care in rural areas remain critical barriers to widespread adoption.

Chronic Venous Occlusions Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.80% over the forecast period (2025-2032)

Based on product type segmentation, Venous stents and anticoagulants was predicted to show maximum market share in the year 2024

Based on Treatment Type segmentation, Endovenous ablation and thrombolytic therapy was the leading Treatment Type in 2024

Based on Diagnosis segmentation, Duplex Ultrasound was the leading Diagnosis in 2024

On the basis of region, North America was the leading revenue generator in 2024

Chronic Venous Occlusions Treatment Market- Segmentation Analysis:

The Global Chronic Venous Occlusions Treatment Market is segmented on the basis of Product Type, Treatment Type, Diagnosis, End-User, and Region.

The market is divided into four categories based on product type: Compression stockings, venous stents, anticoagulants, sclerotherapy agents, and others. Venous stents and anticoagulants dominate due to their efficacy in treating severe occlusions, while compression stockings remain popular for early-stage management and preventive care.

The market is divided into two categories based on Treatment Type: Compression therapy, pharmacological treatment, endovenous ablation, surgical interventions, and thrombolytic therapy. Endovenous ablation and thrombolytic therapy are widely used due to their minimally invasive nature and effectiveness, while compression therapy remains widely used for early-stage management.

Chronic Venous Occlusions Treatment Market- Geographical Insights

The Chronic Venous Occlusions (CVO) Treatment Market exhibits significant regional variation, driven by differences in healthcare infrastructure, disease prevalence, and access to advanced treatments. North America dominates the market, supported by a high prevalence of venous disorders, robust healthcare systems, and early adoption of innovative technologies, with the U.S. accounting for a substantial share due to rising cases of deep vein thrombosis and chronic venous insufficiency. Europe follows closely, driven by aging populations and government-funded healthcare initiatives, particularly in countries like Germany and the UK. The Asia-Pacific region is expected to witness rapid growth due to increasing healthcare expenditure, improving access to medical facilities, and a growing awareness of venous diseases, with countries like China and India leading the way. Meanwhile, Latin America and the Middle East & Africa face challenges such as limited healthcare access but are gradually expanding their market presence through investments in healthcare infrastructure and rising adoption of minimally invasive treatments.

Chronic Venous Occlusions Treatment Market- Competitive Landscape:

The Chronic Venous Occlusions (CVO) Treatment Market features a competitive landscape characterized by the presence of established medical device companies, emerging players, and strategic collaborations aimed at innovation and market expansion. Key players such as Medtronic, Boston Scientific, and Philips Healthcare dominate the market, leveraging their extensive product portfolios and strong distribution networks to maintain a competitive edge. These companies are actively investing in research and development to introduce advanced solutions like bioabsorbable stents and next-generation thrombolysis devices. Smaller firms and startups are also gaining traction by focusing on niche segments and cost-effective treatments. Strategic partnerships, mergers, and acquisitions are common, as companies aim to enhance their technological capabilities and geographic reach. Additionally, regulatory approvals and clinical trials play a crucial role in shaping the competitive dynamics, with players striving to meet stringent safety and efficacy standards. The market's competitive intensity is further fueled by increasing demand for minimally invasive treatments and the growing prevalence of venous disorders worldwide.

Recent Developments:

In June 2024, Philips has launched the Duo Venous Stent System, a device to treat symptomatic venous outflow obstruction in chronic venous insufficiency (CVI) patients. The system, comprised of two stents, is designed for the unique challenges of venous anatomy and demonstrated safety and efficacy in the VIVID study.

In July 2024, Inari expanded its device portfolio with FDA-cleared VenaCore, a minimally invasive thrombectomy catheter for peripheral vasculature. Featuring a notched coring element and collapsible handle, VenaCore efficiently debulks and removes tough venous occlusions, enhancing treatment for complex vascular blockages.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CHRONIC VENOUS OCCLUSIONS TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GLOBAL CHRONIC VENOUS OCCLUSIONS TREATMENT MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL CHRONIC VENOUS OCCLUSIONS TREATMENT MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL CHRONIC VENOUS OCCLUSIONS TREATMENT MARKET, BY DIAGNOSIS- MARKET ANALYSIS, 2019 - 2032

GLOBAL CHRONIC VENOUS OCCLUSIONS TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

GLOBAL CHRONIC VENOUS OCCLUSIONS TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Chronic Venous Occlusions Treatment Market Overview

2. Executive Summary

3. Chronic Venous Occlusions Treatment Key Market Trends

4. Chronic Venous Occlusions Treatment Industry Study

5. Chronic Venous Occlusions Treatment Market: Impact of Escalating Geopolitical Tensions

6. Chronic Venous Occlusions Treatment Market Landscape

7. Chronic Venous Occlusions Treatment Market - By Product Type

8. Chronic Venous Occlusions Treatment Market - By Treatment Type

9. Chronic Venous Occlusions Treatment Market - By Diagnosis

10. Chronic Venous Occlusions Treatment Market - By End-User

11. Chronic Venous Occlusions Treatment Market- By Geography

12. Key Vendor Analysis- Chronic Venous Occlusions Treatment Industry

13. 360 Degree AnalystView

14. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â